Acute‐phase response · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · people with familial Mediterranean fever
Rilonacept showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attacksa · people with familial Mediterranean fever
1 finding from 1 review
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Pain resolution · people with SCD
1 finding from 1 review
Frequency of pain crises in the · people with SCD
Inhaled nitric oxide showed no clear difference in frequency of pain crises in the compared with placebo (low certainty).
2 findings from 1 review
Adverse events · people with SCD
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported symptom score  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum: volume · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported symptom score: cough, wheeze and exercise tolerance · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes participant‐reported symptom score: cough, wheeze and exercise… compared with placebo (very low certainty).
1 finding from 1 review
Adverse events  · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Sputum: volume · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes sputum volume (mL) compared with placebo (very low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
1 finding from 1 review